 |
市場調查報告書
商品編碼
1190191
癌症登記軟體市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)Cancer Registry Software Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在 2022 年至 2027 年的預測期內，癌症登記軟體市場的複合年增長率預計為 10.3%。
COVID-19 大流行導致大流行期間癌症診斷的顯著下降以及化療和手術等癌症支持治療的減少。 此外，2020 年 6 月，歐洲胃腸內窺鏡學會和歐洲胃腸內窺鏡護士協會發布了指南。 在指導文件中，醫生被建議在內鏡切除後、手術切除後和息肉切除術後推遲癌症。 他們還建議由於感染風險而推遲對高危癌症患者的篩查，進一步減少治療程序。
同樣，2022 年 1 月發表的一項題為“COVID-19 大流行對基於人群的癌症登記的影響”的研究發現，全球許多癌症都處於 COVID-19 大流行的早期階段。據報導，註冊干擾了操作。 政府承諾支持未來的登記業務作為疾病控制的一項資產，以及向電子報告系統的過渡，將有助於確保全球癌症監測的可持續性。
預計未來的市場增長將受到癌症患病率上升、護理質量提高和醫療保健成本降低等因素的推動，再加上主要參與者的近期發展，例如產品/服務發布和兼併/收購。 根據全球癌症觀察站（Globocan）2020年的統計數據，2020年全球將新增1930萬癌症患者，而且這些患者的數量預計還會增加，到2040年將達到3020萬。已經過去了。 此外，根據國際癌症研究機構 (IARC) 從 2021 年 7 月更新的估計，到 2040 年，全球將新增 2750 萬癌症患者和 1630 萬死亡病例，預計將增加。 如此高的負擔在識別與癌症患病率和治療相關的趨勢方面提供了顯著優勢，增加了對癌症□□登記軟體的需求。
同樣，產品批准和發布也是市場增長的因素。 例如，2020 年 4 月，Elekta 的基於雲的搜索和存儲軟體 ProKnow 獲得了 CE 標誌。 借助供應商中立的 ProKnow，任何放射治療部門都可以將大量數據安全地上傳到 ProKnow 的雲服務器，用於存儲、分佈輪廓、計劃評估和同行評審以及關鍵指標分析（成果技術設施間合作等）。 ).
此外，2021 年 8 月，北愛爾蘭癌症登記處 IARC 將提供新軟體來促進癌症分期，從而更有效地收集可比數據以用於國家癌症管理。旨在改進 此外，2020 年 10 月，MOVEMBER 將推出世界上最大的前列腺癌患者登記網絡，利用超過 130,000 名男性的“真實世界”經驗來幫助治療和護理這種疾病。有能力改變 這些努力通過改善基礎設施和提供更高效和更具成本效益的數字解決方案來降低成本。 因此，由於上述因素，預計未來市場將增長。 然而，對患者數據隱私和安□□全的擔憂預計會抑制市場增長。
主要市場趨勢
預計在預測期內醫院和診所將佔據重要的市場份額
醫院部門是所研究市場增長的主要貢獻者，因為大多數醫院都擁有完善的基礎設施。 癌症相關手術的增加增加了對醫院的需求。 患者依賴醫院作為他們的初級保健中心，預計在預測期內這種情況將持續下去。
在一些中歐和東歐 (CEE) 國家，醫療保健支出佔 GDP 的比例落後於較富裕的歐盟 (EU) 國家。 包括波蘭和捷克共和國在內的一些國家正感受到增加醫療保健投資的政治壓力。 歐盟出版物 Sifted 於 2020 年 11 月報導稱，歐洲有 626 家積極投資的數字健康公司，其中 63% 是在過去五年推出的。 此外，每個國家的手術數量也在推動市場的增長。 例如，The Innovative Partnership For Action Against Cancer 文章“解決放射腫瘤學和癌症手術的報銷問題：挑戰和選擇”據報導是最常見的 丹麥每年進行 100 多例胰腺手術。 如此高的手術數量代表了患者對手術的採用率很高，預計隨著時間的推移會出現增長。 手術數量的增加預計會增加患者對醫院的偏好，因為醫院的更高投資和資金使他們能夠提供比其他設施更好的護理。
此外，醫院癌症登記軟體的可用性也是市場增長的因素之一。 例如，2021 年 9 月，印度醫學研究委員會 (ICMR) 發布了一份題為“印度癌症臨床病理學概況”的報告。 2021 年基於醫院的癌症登記報告”，根據 NCRP，2012 年至 2019 年間，96 家醫院登記了 13,32,207 例癌症病例。 其中，6,10,084 個被納入分析。 因此，醫院內癌症登記軟體的可用性為患者提供了額外的好處。 由於這些優勢，癌症登記軟體市場有望在未來增長。
因此，由於上述因素，該細分市場在未來可能會增長。
北美有望在預測期內主導市場
預計北美地區將主導市場。 預計在預測期內，癌症等慢性病的流行和新產品的推出將推動該地區的市場。
根據《美國癌症協會雜誌》發表的《Cancer Statistics 2021》，美國估計有 190 萬新診斷的癌症患者和 608,570 人死於癌症，這是市場預計將推動 此外，根據“Globocan 2020”，到 2020 年，該國的新癌症病例數將為 274,364 例，預計到 2040 年這一數字將上升到 400,564 例。 因此，該國癌症患者負擔的增加預計將推動市場增長。
此外，癌症是墨西哥最常見的慢性疾病之一，根據 Globocan 2020 報告，2020 年約有 195,499 例新的癌症診斷，其中 90,222 例將因癌症死亡。 最常見的癌症是乳腺癌、前列腺癌、結直腸癌、甲狀腺癌和宮頸癌。 此外，根據 Globocan 2020，墨西哥的癌症發病率預計到 2030 年將達到 254,665 人，到 2040 年將達到 323,432 人，並有望快速增長。 因此，該研究涵蓋的市場預計將在本研究的預測期內增長。
同樣，癌症登記處採用率的提高也有望促進市場增長。 根據美國疾病控制和預防中心的數據，截至 2022 年 1 月，超過 98% 的國家癌症登記計劃 (NPCR) 資助的癌症登記處至少使用一種 Registry Plus 產品，其中一半您正在使用不止一種產品. Registry Plus 產品已成為許多癌症登記處的通用平台，符合 NPCR 電子數據交換標準，並有助於簡化和自動化登記操作。 這樣的採用率預計將推動未來的市場增長。
競爭格局
由於技術進步，大多數參與者都位於發展中國家。 然而，由於現代世界的互聯便利，這些參與者也在向新興國家擴張，並試圖在這些國家建立市場。 市場部分分散，由幾個主要參與者組成。 目前主導市場的公司包括 C/NET Solutions、Elekta、McKesson Corporation、IBM Corporation 和 Siemens Healthineers。
其他好處
- Excel 格式的市場預測 (ME) 表
- 三個月的分析師支持
內容
第1章介紹
- 研究假設和市場定義
- 調查範圍
第2章研究方法論
第 3 章執行摘要
第4章市場動態
- 市場概覽
- 市場驅動力
- 癌症患病率增加
- 提高醫療質量並降低醫療成本
- 市場製約因素
- 患者數據隱私和安□□全問題
- 波特的五力分析
- 新進入者的威脅
- 買方/消費者議價能力
- 供應商的議價能力
- 替代品的威脅
- 競爭公司之間的敵對關係
第 5 章市場細分（基於價值的市場規模：百萬美元）
- 按部署模型
- 本地
- 雲類型
- 按數據庫類型
- 商業數據庫
- 公共數據庫
- 最終用戶
- 政府/第三方組織
- 私人付款人
- 醫院和診所
- 其他
- 按地區
- 北美
- 美國
- 加拿大
- 墨西哥
- 歐洲
- 德國
- 英國
- 法國
- 意大利
- 西班牙
- 其他歐洲地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳大利亞
- 韓國
- 其他亞太地區
- 中東和非洲
- 海灣合作委員會
- 南非
- 其他中東和非洲地區
- 南美洲地區
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章競爭格局
- 公司簡介
- C/NET Solutions
- Conduent, Inc
- Electronic Registry System, Inc.
- Elekta
- himagine solutions
- IBM Corporation
- McKesson Corporation
- NeuralFrame, Inc
- Onco, Inc.
- Ordinal Data, Inc
- Rocky Mountain Cancer Data Systems
- Siemens Healthineers
第7章 市場機會與今後動向
The cancer registry software market is projected to register a CAGR of 10.3% during the forecast period 2022-2027.
Due to the COVID-19 pandemic, the diagnostics for cancer decreased significantly during the pandemic, and there has been a decline in chemotherapy, surgery, and other supportive treatments for cancer. Further, in June 2020, guidance was issued by the European Society of Gastrointestinal Endoscopy and the European Society of Gastroenterology and Endoscopy Nurses and Associates. The guidance document advised that doctors postpone post-endoscopic resection, surgical resection of cancer, and post-polypectomy cancer. They also advised that screening of high-risk patients for cancer should also be postponed due to the risk of infection, which further led to the reduction in the treatment procedures.
Similarly, in January 2022, a research study published titled "Impact of the COVID-19 pandemic on population-based cancer registry" stated that many cancer registries worldwide reported disruption to their operations during the early COVID-19 pandemic. Governmental commitment to support future registry operations as an asset to disease control, alongside a move toward electronic reporting systems, will help to ensure the sustainability of cancer surveillance worldwide.
Factors such as increasing prevalence of cancer, and improving quality of care, and reducing healthcare costs coupled with recent developments by key players such as product/service launches and mergers & acquisitions are expected to increase the market growth in the upcoming future. According to the Global Cancer Observatory (Globocan) 2020 statistics, Globally, there were 19.3 million new cancer cases in 2020, these cases are expected to increase and reach up to 30.2 million in 2040. Additionally, according to estimates from the International Agency for Research on Cancer (IARC) updates from July 2021, by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Such high burdens will increase the demand for cancer registry software as it would provide significant advantages to identifying the trend related to the prevalence and treatment of cancer.
Similarly, product approval and launches are other factors for the growth of the market. For instance, in April 2020, Elekta received a CE mark for its ProKnow cloud-based retrieval and storage software. With vendor-neutral ProKnow, any radiation therapy department can securely upload massive volumes of data to ProKnow's cloud server for storage, distributed contouring, plan evaluation and peer review, and analysis of key metrics - including outcomes technique evaluations and intra- and inter-institutional collaborations.
Additionally, in August 2021, IARC, The Northern Ireland Cancer Registry, and new software to facilitate cancer staging, aiming to improve national cancer control with a more effective collection of comparable data. Furthermore, in October 2020, MOVEMBER launched the world's largest network of prostate cancer patient registries, which will have the power to transform treatment and care of the disease by harnessing the 'real world' experiences of over 130,000 men. Such initiative improves the infrastructure and brings the cost down by providing a more efficient and cost-effective digital solution. Hence, due to the abovementioned factors, the market is expected to grow in the future. However, privacy and security concerns for patient data will be a restraint in the market growth.
Key Market Trends
Hospital & Medical Practice are Expected to Hold a Significant Market Share Over the Forecast Period
The hospital segment highly contributes to the growth of the studied market since the majority of the hospitals have a well-developed infrastructure. The rising cancer-related procedures are augmenting the demand of hospitals. Patients have been relying on hospitals as primary care centers, which is likely to continue during the forecast period.
In several Central and Eastern European (CEE) countries, healthcare spending as a percentage of GDP has lagged that of wealthier European Union (EU) nations. Some nations, notably Poland and the Czech Republic, now feel political pressure to increase healthcare investment. The EU publication Sifted reported in November 2020 that Europe had 626 actively funded digital health companies, with 63% of them launched in the prior five years. The high number of surgeries in different nations is also propelling the growth of the market. For Instance, The Innovative Partnership For Action Against Cancer article titled "Tackling reimbursement for radiation oncology and cancer surgery: challenges and options'' published in October 2020, reported that despite the small size of Denmark's population, the minimum number of cases is among the highest in Europe. In Denmark, more than 100 per year pancreatic surgeries are performed. Such a high number of surgeries depicts the high adoption of surgery among the patients and thus is expected to show growth over time. Hence, increasing surgeries would increase the patient preference for hospitals as it would provide them better care than other facilities due to high investments and funding available to the hospitals.
The availability of cancer registry software in hospitals is another factor in the growth of the market. For instance, in September 2021, the Indian Council of medical research (ICMR) published its report titled "Clinicopathological Profile of Cancers in India: A Report of Hospital-Based Cancer Registries, 2021," which stated that under the NCRP, 13,32,207 cancer cases were registered from 96 hospitals during 2012-19. Out of these, 6,10,084 cases were included for analysis. Thus, the availability of cancer registry software in the hospital provides additional advantages to the patients. Due to these advantages, the cancer registry software market is expected to grow in the upcoming future.
Hence, due to the above-mentioned factors, the market segment is likely to grow in the future.
North America is Expected to Dominate the Market Over the Forecast Period
The North American region is expected to dominate the market. The increasing prevalence of chronic disorders like cancer and new product launches are expected to drive the market in the region during the forecast period.
According to Cancer Statistics 2021, published in the American Cancer Society Journal, there are an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in United States, which will drive the market significantly. moreover, according to Globocan 2020, the number of new cancer cases in the country was 274,364 in 2020, and this number is expected to increase to 400,564 by 2040. Thus, the growing burden of cancer cases in the country is expected to fuel the growth of the market.
Moreover, cancer is one of the most prevalent forms of chronic disease in Mexico, and as per the report of Globocan 2020, about 195,499 people were newly diagnosed with cancer in 2020, and 90,222 died because of it. The most prevalent forms of cancer were breast, prostate, colorectum, thyroid, and cervix uteri cancer. Furthermore, as per the Globocan 2020, the cancer incidence in Mexico is expected to reach 254,665 by 2030 and 323,432 by 2040, and thus, with the increasing burden of cancer cases in the country, the adoption of cancer registry software is expected to surge. Therefore, the studied market is expected to grow over the forecast period of the study.
Similarly, increasing the adoption of cancer registries would also increase the market growth. According to the Centers for Disease Control and Prevention, as of January 2022, over 98% of National Program of Cancer Registries (NPCR) funded cancer registries use at least one Registry Plus product, with more than half of those using two or more products. Registry Plus products have become a common platform among many cancer registries, helping them meet NPCR's standards for electronic data exchange, and streamlining and automating registry operations. Such an adoption rate would increase market growth in the upcoming future.
Competitive Landscape
Most of the players are based in developing counties due to more technological advancements. But due to the ease of connectivity in modern times, these players have also penetrated developing countries and are trying to establish a market in these countries as well. The market is partially fragmented and consists of several major players. Some of the companies which are currently dominating the market are C/NET Solutions, Elekta, McKesson Corporation, IBM Corporation, and Siemens Healthineers, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Cancer
- 4.2.2 Improving Quality of Care and Reducing Healthcare Costs
- 4.3 Market Restraints
- 4.3.1 Privacy and Security Concerns for Patient Data
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
- 5.1 By Deployment Model
- 5.1.1 On-Premise
- 5.1.2 Cloud-based
- 5.2 By Database Type
- 5.2.1 Commercial Database
- 5.2.2 Public Database
- 5.3 By End Use
- 5.3.1 Government & Third Party
- 5.3.2 Private Payers
- 5.3.3 Hospital & Medical Practice
- 5.3.4 Others
- 5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 C/NET Solutions
- 6.1.2 Conduent, Inc
- 6.1.3 Electronic Registry System, Inc.
- 6.1.4 Elekta
- 6.1.5 himagine solutions
- 6.1.6 IBM Corporation
- 6.1.7 McKesson Corporation
- 6.1.8 NeuralFrame, Inc
- 6.1.9 Onco, Inc.
- 6.1.10 Ordinal Data, Inc
- 6.1.11 Rocky Mountain Cancer Data Systems
- 6.1.12 Siemens Healthineers
